Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2013 Apr 16.

Published in final edited form as: Aging Cell. 2011 Apr 14;10(4):604–621. doi: 10.1111/j.1474-9726.2011.00700.x

A. Scheme of the TA-65 treatment plan. B. Fold change in mTERT mRNA levels 3 months post treatment in different tissues of 2 years old TA-65 treated mice compared to age-matched controls. mTERT mRNA values were normalized to actin. Student’s t-test was used for statistical comparisons. C. mTERT protein expression in liver extracts from control or 2 years old TA-65 treated mice (NS: non-specific band) using a mTERT antibody previously validated by us (Martinez et al. 2010)). As controls, mTERT protein expression is detected in wild-type MEFs but not in TERT^−/− MEFs (Liu et al. 2000). Quantification of mTERT expression is presented in the right panel (fold changes in telomerase activity are plotted, comparing to the values obtained for the control situation (without TA-65)). The quantification was made with Scion Image Software. Student’s t-test was used for statistical comparisons. D. Fold change in JunB mRNA levels 3 months post treatment in different tissues of 2 years old TA-65 treated mice compared to age-matched controls. JunB mRNA values were normalized to actin. E. Fold change in c-Myc mRNA levels 3 months post treatment in different tissues of 2 years old TA-65 treated mice compared to age-matched controls. c-Myc mRNA values were normalized to actin. Student’s t-test was used for statistical comparisons. F. Percentage of c-Myc positive cells, quantified from at least 3 independent mice. Measures were realized post mortem in cancer-free mice. Student’s t-test was used for statistical comparisons. At least 5 high power fields (HPF, x100) were used per independent mouse (around 3000 cells scored per mouse, AxioVision was used for image analysis). G. Representative IHC of c-Myc staining in either control or TA-65 treated 2 years old female mice. H. Hypothetical model of action of TA-65 based in ours and previous results.

A. Scheme of the TA-65 treatment plan. B. Fold change in mTERT mRNA levels 3 months post treatment in different tissues of 2 years old TA-65 treated mice compared to age-matched controls. mTERT mRNA values were normalized to actin. Student’s t-test was used for statistical comparisons. C. mTERT protein expression in liver extracts from control or 2 years old TA-65 treated mice (NS: non-specific band) using a mTERT antibody previously validated by us (Martinez et al. 2010)). As controls, mTERT protein expression is detected in wild-type MEFs but not in TERT^−/− MEFs (Liu et al. 2000). Quantification of mTERT expression is presented in the right panel (fold changes in telomerase activity are plotted, comparing to the values obtained for the control situation (without TA-65)). The quantification was made with Scion Image Software. Student’s t-test was used for statistical comparisons. D. Fold change in JunB mRNA levels 3 months post treatment in different tissues of 2 years old TA-65 treated mice compared to age-matched controls. JunB mRNA values were normalized to actin. E. Fold change in c-Myc mRNA levels 3 months post treatment in different tissues of 2 years old TA-65 treated mice compared to age-matched controls. c-Myc mRNA values were normalized to actin. Student’s t-test was used for statistical comparisons. F. Percentage of c-Myc positive cells, quantified from at least 3 independent mice. Measures were realized post mortem in cancer-free mice. Student’s t-test was used for statistical comparisons. At least 5 high power fields (HPF, x100) were used per independent mouse (around 3000 cells scored per mouse, AxioVision was used for image analysis). G. Representative IHC of c-Myc staining in either control or TA-65 treated 2 years old female mice. H. Hypothetical model of action of TA-65 based in ours and previous results.